Imaging tumour hypoxia with positron emission tomography

British Journal of Cancer

Volumn 112, Issue 2, 2015, Pages 238-250

  Fleming, I N ^a   Manavaki, R ^b   Blower, P J ^c   West, C ^d   Williams, K J ^e,f   Harris, A L ^g   Domarkas, J ^h   Lord, S ^g   Baldry, C ^c   Gilbert, F J ^b,f  

^a Aberdeen Biomedical Imaging Centre   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ST THOMAS HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f Cambridge and Manchester   (United Kingdom)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Cancer; Hypoxia; Imaging; Oncology; Positron emission tomography (PET); Radiotracer

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 2 (2 NITRO 1 IMIDAZOLYLMETHOXY) 1,3 PROPANEDIOL F 18; 3 FLUORO 2 [4 [(2 NITRO 1H IMIDAZOL 1 YL)METHYL] 1H 1,2,3 TRIAZOL 1 YL)PROPAN 1 OL F 18; COPPER DIACETYL BIS(N4 METHYLTHIOSEMICARBAZONE); FLUOROAZOMYCIN ARABINOFURANOSIDE F 18; FLUOROERYTHRONITROIMIDAZOLE F 18; NITROIMIDAZOLE DERIVATIVE; TRACER; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

CANCER PROGNOSIS; CANCER SURVIVAL; HUMAN; HYPOXIA; IMAGE GUIDED RADIOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; META ANALYSIS (TOPIC); MICROVASCULATURE; OVERALL SURVIVAL; OXIDATIVE STRESS; OXYGEN CONCENTRATION; OXYGEN DIFFUSION; OXYGEN SUPPLY; PHYSIOLOGICAL PROCESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE ESCALATION; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR BLOOD FLOW; TUMOR MICROENVIRONMENT; TUMOUR HYPOXIA; VALIDATION STUDY; CELL HYPOXIA; COMPUTER ASSISTED RADIOTHERAPY; DIAGNOSTIC USE; METABOLISM; NEOPLASM; SCINTISCANNING;

CELL HYPOXIA; HUMANS; NEOPLASMS; NITROIMIDAZOLES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84921996867     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.610     Document Type: Review

References (90)

1. 18F]FMISO-PET in HNSCC: When is the contrast best? Nuklearmedizin 50(1): 22-27.
2. 18F-fluoromisonidazole PET and polarographic needle electrodes in human soft tissue tumours. Radiother Oncol 67(3): 339-344.
3. 18F-FRP170 as a hypoxic cell tracer correlates with intratumoral oxygen pressure in glioblastoma. Mol Imaging Biol 16(1): 1-9.
4. 18F-fluoroazomycin arabinoside in stage III-IV non-small cell lung cancer patients. J Nucl Med 54(8): 1175-1180.
5. Bristow RG, Hill RP (2008) Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3): 180-192.
6. 2O. J Nucl Med 45(11): 1851-1859.
7. Chao KSC, Bosch WR, Mutic S, Lewis JS, Dehdashti F, Mintun MA, Dempsey JF, Perez CA, Purdy JA, Welch MJ (2001) A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49(4): 1171-1182.
8. Chapman JD (1979) Hypoxic sensitisers - Implications for radiation therapy. N Engl J Med 301(26): 1429-1432.
9. 18F-FMISO. Nucl Med Commun 33(10): 1096-1102.
10. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer. J Nucl Med 54(3): 333-340.
11. 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47(3): 410-418.
12. 18F-FDG PET. J Nucl Med 47(12): 1921-1926.
13. Dearling JLJ, Packard AB (2010) Some thoughts on the mechanism of cellular trapping of Cu(II)-ATSM. Nucl Med Biol 37(3): 237-243.
14. 60Cu-ATSM: Relationship to therapeutic response - a preliminary report. Int J Radiat Oncol Biol Phys 55(5): 1233-1238.
15. 60Cu-ATSM. Eur J Nucl Med Mol Imaging 30(6): 844-850.
16. 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 49(2): 201-205.
17. 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum 51(11): 1641-1648.
18. 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 50(7): 1020-1027.
19. 18F]Fluoromisonidazole PET and immunohistochemistry. Br J Cancer 91(11): 1947-1954.
20. 18F-Misonidazole and PET: changes of kinetics during radiotherapy of head-and-neck cancer. Radiother Oncol 83(3): 406-410.
21. 18F]-2-fluoro-2′-deoxyglucose): an appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol 180(10): 616-622.
22. 18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. BMC Cancer 6: 51.
23. 18F] fluorodeoxyglucose positron emission tomography: validated methods for the evaluation of therapy-relevant tumor oxygenation or only bricks in the puzzle of tumor hypoxia? BMC Cancer 7: 113.
24. 18F-FAZA PET/CT utilizing multimodality fusion techniques. Eur J Nucl Med Mol Imaging 2011: 1-8.
25. Geets X, Grégoire V, Lee JA (2013) Implementation of hypoxia PET imaging in radiation therapy planning. Q J Nucl Med Mol Imaging 57(3): 271-282.
26. 60Cu-ATSM in cancer of the uterine cervix. Mol Imaging Biol 9(5): 278-283.
27. Grosu AL, Souvatzoglou M, Röper B, Dobritz M, Wiedenmann N, Jacob V, Wester HJ, Reischl G, Machulla HJ, Schwaiger M, Molls M, Piert M (2007) Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 69(2): 541-551.
28. 64Cu-ATSM. J Nucl Med 55(3): 488-494.
29. 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. Nucl Med Commun 34(2): 155-161.
30. Hicks RJ, Rischin D, Fisher R, Binns D, Scott AM, Peters LJ (2005) Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent. Eur J Nucl Med Mol Imaging 32(12): 1384-1391.
31. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 26(1): 45-50.
32. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J (2012) Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 9(12): 674-687.
33. 18F-fluoroerythronitroimidazole integrated PET/CT and immunohistochemical studies in non-small cell lung cancer. Clin Nucl Med 38(8): 591-596.
34. 64Cu-ATSM in vitro and in vivo. J Nucl Med 55(1): 128-134.
35. 18F-fluoromisonidazole PET/CT study. J Nucl Med 52(7): 1048-1055.
36. Jubb AM, Buffa FM, Harris AL (2010) Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis. J Cell Mol Med 14(1-2): 18-29.
37. 18F-FRP170 as a new PET tracer for imaging hypoxia. Ann Nucl Med 21(2): 101-107.
38. 18F-fluoromisonidazole positron emission tomography before treatment is a predictor of radiotherapy outcome and survival prognosis in patients with head and neck squamous cell carcinoma. Ann Nucl Med 25(9): 625-633.
39. Koh WJ, Bergman KS, Rasey JS, Peterson LM, Evans ML, Graham MM, Grierson JR, Lindsley KL, Lewellen TK, Krohn KA, Griffin TW (1995) Evaluation of oxygenation status during fractionated radiotherapy in human nonsmall cell lung cancers using [F-18]fluoromisonidazole positron emission tomography. Int J Radiat Oncol Biol Phys 33(2): 391-398.
40. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, Chan K, Zanzonico PB, Greco C, Ling CC, Humm JL, Schöder H (2008) Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys 70(1): 2-13.
41. 18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 75(1): 101-108.
42. 18F-fluoromisonidazole. Semin Nucl Med 37(6): 451-461.
43. 18F]Fluoroerythronitroimidazole PET. J Nucl Med 42(11): 1643-1652.
44. 18F]FETNIM) and PET using the tumour to plasma ratio. Eur J Nucl Med Mol Imaging 30(1): 101-108.
45. Lehtiö K, Eskola O, Viljanen T, Oikonen V, Grönroos T, Sillanmäki L, Grénman R, Minn H (2004) Imaging perfusion and hypoxia with PET to predict radiotherapy response in head-and-neck cancer. Int J Radiat Oncol Biol Phys 59(4): 971-982.
46. 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 49(7): 1177-1182.
47. 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer 11(5): 335-340.
48. 18F-FDG in lung cancer. J Nucl Med 50(12): 1948-1953.
49. 18F]Fluoromisonidazole positron emission tomography. Int J Oncol 30(4): 873-881.
50. 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. Nucl Med Biol 32(2): 147-156.
51. 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study. Ann Nucl Med 25(5): 339-345.
52. 18F]fluoromisonidazole PET imaging. Phys Med Biol 57(6): 1675-1684.
53. 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode. Acta Oncol 49(7): 934-940.
54. Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, Alsner J, Sørensen BS, Toustrup K, Jakobsen S, Petersen J, Petersen H, Theil J, Nordsmark M, Overgaard J (2012) FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol 105(1): 14-20.
55. 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 70(1): 235-242.
56. Nyflot MJ, Harari PM, Yip S, Perlman SB, Jeraj R (2012) Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx. Radiother Oncol 105(1): 36-40.
57. 2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61(5): 1493-1502.
58. 18F-fluoromisonidazole pet for head and neck cancer. J Nucl Med 54(2): 201-207.
59. Overgaard J (2011) Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck - a systematic review and meta-analysis. Radiother Oncol 100(1): 22-32.
60. 18F-FAZA). Eur J Nucl Med Mol Imaging 36(10): 1565-1573.
61. 18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging 30(5): 695-704.
62. 18F]]Fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 10(7): 2245-2252.
63. Rajendran JG, Schwartz DL, O'Sullivan J, Peterson LM, Ng P, Scharnhorst J, Grierson JR, Krohn KA (2006) Tumor hypoxia imaging with [F-18] fluoromisonidazole positron emission tomography in head and neck cancer. Clin Cancer Res 12(18): 5435-5441.
64. 18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36(2): 417-428.
65. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group study 98.02. J Clin Oncol 24(13): 2098-2104.
66. Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, Stroobants S, Penninckx F, Haustermans K (2008) Biological image-guided radiotherapy in rectal cancer: Is there a role for FMISO or FLT, next to FDG? Acta Oncol 47(7): 1237-1248.
67. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1a expression in oral squamous cell carcinoma. J Nucl Med 54(7): 1060-1065.
68. 18FAZA) PET in the setting of MRI guided adaptive radiotherapy in cervical cancer. Acta Oncol 49(7): 941-947.
69. 18F-FMISO) PET/CT in suspected or proven pancreatic cancer. Clin Nucl Med 38(1): 1-6.
70. Semenza GL (2004) Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 19(4): 176-182.
71. 2O in patients with head and neck tumors. J Nucl Med 51(9): 1386-1394.
72. 18F-labeled 2-nitroimidazole analog: clinical article. J Neurosurg 113(2): 358-368.
73. 18F]FAZA PET in head and neck cancer patients: a pilot study. Eur J Nucl Med Mol Imaging 34(10): 1566-1575.
74. 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med 50(1): 36-44.
75. 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann Nucl Med 14(5): 323-328.
76. 62Cu-diacetyl-bis (N4- methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1a expression in patients with glioma. Am J Neuroradiol 34(1): 92-99.
77. 18F-fluoromisonidazole PET correlates with radiation treatment outcome in head-and-neck cancer. BMC Cancer 5: 152.
78. 18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 80(2): 151-156.
79. 18F-fluorothymidine PET images in lung cancer. J Nucl Med 54(9): 1543-1550.
80. 18F-FAZA PET in patients with locally advanced non-small cell lung cancer treated with definitive chemoradiotherapy. J Med Imaging Radiat Oncol 57(4): 475-481.
81. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF (1992) Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33(12): 2133-2137.
82. Vaupel P, Harrison L (2004) Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 9(Suppl 5): 4-9.
83. 18F-fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study. Radiother Oncol 98(1): 109-116.
84. 18F-FETNIM PET/CT. Clin Nucl Med 37(11): 1065-1068.
85. 18F-FMISO PET. Med Phys 36(10): 4400-4408.
86. Wilson WR, Hay MP (2011) Targeting hypoxia in cancer therapy. Nat Rev Cancer 11(6): 393-410.
87. 18F]fluoromisonidazole uptake after neoadjuvant chemotherapy for head and neck squamous cell carcinoma. Mol Imaging Biol 13(2): 227-231.
88. 18F-FETNIM PET in esophageal squamous cell carcinoma: a pilot clinical study. Dis Esophagus 25(1): 54-61.
89. 18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters. Radiother Oncol 109(1): 58-64.
90. 2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 33(12): 1426-1431.